Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares gapped up before the market opened on Tuesday . The stock had previously closed at $2.86, but opened at $2.95. Adamis Pharmaceuticals Corp. shares last traded at $3.16, with a volume of 279,878 shares trading hands.

Separately, Maxim Group upped their price objective on shares of Adamis Pharmaceuticals Corp. from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, March 29th.

The stock’s market capitalization is $46.37 million. The stock has a 50 day moving average price of $5.02 and a 200 day moving average price of $5.77.

In related news, SVP David J. Marguglio sold 12,000 shares of the stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $7.52, for a total value of $90,240.00. Following the completion of the transaction, the senior vice president now owns 118,227 shares in the company, valued at approximately $889,067.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David J. Marguglio sold 4,860 shares of the stock in a transaction on Monday, May 9th. The shares were sold at an average price of $10.00, for a total value of $48,600.00. Following the completion of the transaction, the senior vice president now owns 106,227 shares of the company’s stock, valued at approximately $1,062,270. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.